lobbying_activities: 3330495
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3330495 | 5bef0670-8d38-40ec-b45b-5a06061e61a8 | Q1 | PUBLIC CITIZEN | 32362 | PUBLIC CITIZEN | 2025 | first_quarter | PHA | anti-obesity medication pricing, HHS secretary nomination, Medicare drug price negotiation, international reference price negotiation price caps, number of drugs negotiated, out of pocket caps, inflation rebates, negotiation delay periods, direct-to-consumer pharmaceutical telehealth; Medicare drug price negotiation; HHS nomination, Deputy HHS Secretary, and CMS nominations, Medicare drug price negotiation, Capping Prescription Costs Act, National Institute for Biomedical Research and Development legislation, Protecting Patients from Deceptive Drug Ads Online Act, H.R. 946 Orphan CURES Act; Medicare drug price negotiation eligibility delay period, S.652 Protecting Patients from Deceptive Drug Ads Online Act, EPIC Act (H.R. 1492 / S. 832), ORPHAN Cures Act (H.R.946), and MINI Act (H.R.1672); Medicare drug price negotiation delay periods and exemptions. | HOUSE OF REPRESENTATIVES,SENATE | 76570 | 0 | 0 | 2025-04-09T14:04:19-04:00 |